Compound Radar

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis

Price $42.43
Market cap $2.54B
Next earnings Nov 3, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

60
60/100 Good Quality
  • Financial Health 70
  • Profitability 25
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 45

Why this rating?

Health 60/100 — Good Quality

Strongest Business Quality 75/100
Softest Profitability 25/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Supernus Pharmaceuticals, Inc. (SUPN) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Supernus Pharmaceuticals, Inc. 60/100 (Good Quality) due to high business quality, strong revenue growth, and manageable leverage.

Investment profile

  • Quality High
  • Growth Strong
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • Forward P/E 9.8
  • EV/Revenue 2.66

Profitability

  • Revenue Growth 32.4%
  • Gross Margin 72.9%
  • Operating Margin -2.5%
  • Net Margin -13.2%
  • ROE -10.5%

Financial strength

  • Cash $372.07M
  • Debt $40.17M
  • Net Cash $331.90M
  • Free Cash Flow $45.99M
  • Current Ratio 2.08

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Supernus Pharmaceuticals, Inc. (SUPN).

View Methodology & FAQ →